An interventional study of iCBT-I and GCBT-I in Insomnia, Schizophrenia and Schizoaffective Disorder, sponsored by Helsinki University Central Hospital. Recruiting at 1 site in Finland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Helsinki University Central Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland — 3 open to participants now, 4 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Finland.
Among the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland, this one is the 13th largest by planned enrollment, is the only one that started in 2019, is one of 6 with no phase, and was the 11th registered.
2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.
Browse Sleep Initiation and Maintenance Disorders studies →3 of the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland are open now. Recruiting first, the newest first:
University of Turku · Sites in Finland
Ages 18+
Helsinki University Central Hospital · Sites in Finland
Ages 18–75
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 68 across 2,363 interventional studies indexed under Sleep Initiation and Maintenance Disorders.
Median enrollment 367 across the 16 interventional studies. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 9 most frequent:
Helsinki University Central Hospital is the lead sponsor of 311 studies on the registry; 61 are open to participants now.
Helsinki University Central Hospital has 3 studies filed under Sleep Initiation and Maintenance Disorders — fewer than ten, so there is no comparison to draw.
1 of the studies in Sleep Initiation and Maintenance Disorders with a site in Finland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06827626Finnish Institute of Occupational HealthTailored Treatment of Insomnia in Social and Health Care Sector Shift Workers in Occupational Health Care | 2027-03-15 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Sleep Initiation and Maintenance Disorders with a site in Finland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Sleep problems are pervasive in people with schizophrenia. In our study, our goal is to determine whether we can alleviate sleep symptoms and improve quality of life and well-being in patients with major psychiatric disorders through cognitive behavioral therapy (CBT) delivered via the internet or in groups.
At the same time, the study provides information on factors that are commonly associated with sleep and well-being in patients. The intervention study is conducted as a Randomized Controlled Clinical Trial (RCT), in which subjects are randomized into three groups: 1) Treatment as usual (TAU), 2) TAU and Internet-based therapy for insomnia (ICBT-I), and 3) TAU and group therapy for insomnia (GCBT-I).
Sleep is important for well-being. Lack of sleep and poor quality of sleep (Insomnia) are risk factors for psychiatric and somatic diseases such as depression, cardiovascular disease, diabetes and memory disorders and increases the risk of cognitive errors and accidents.
Psychiatric patients suffer from a wide variety of sleep disorders. Insomnia symptoms are known to increase the likelihood of later depression and even the use of disability pensions due to depression.
Various sleep disorders are also common in patients with schizophrenia. Previous studies on schizophrenia have reported-, symptoms of insomnia, especially the problem of falling asleep and poor sleep quality, circadian rhythm disruption, hypersomnolence and nightmares among the patients.
Cognitive behavioural therapy for insomnia (CBT-I) is an evidence-based treatment for insomnia. CBT-I can be implemented as an individual treatment, on a group basis or via the internet. There is evidence that CBT-I can also be used to treat a patient with a major psychiatric disorders, but randomized clinical trials (RCT) have rarely been published. Our research is based on the hypothesis that symptoms of insomnia in patients with schizophrenia can improved by CBT-I and, further, by improving patients' sleep quality their health and quality of life can also be improved.
The present study is designed to investigate the effect of two different treatment programs as compared to treatment as usual (TAU). The purpose of this study is to determine whether CBT-I can help relieve sleep symptoms and improve quality of life and well-being in patients with schizophrenia. At the same time, the study provides information on factors that are commonly associated with sleep and well-being in patients with major psychiatric disorders. The intervention study is conducted as an RCT, in which subjects are randomized into three groups: 1) Treatment as usual (TAU), 2) TAU and Internet-based therapy for insomnia (ICBT-I), and 3) TAU and group therapy for insomnia (GCBT-I).
The aim of this ongoing randomized controlled trial is to recruit 84 - 120 participants from Hospital District of Helsinki and Uusimaa (HUS) Psychiatry Outpatient Clinics for Psychosis, and they have previously participated in the nationwide SUPER Finland study (a study on genetic mechanisms of psychotic disorders and a part of the Stanley Global Neuropsychiatric Genomics Initiative). The study is performed on a cycle basis with a target of 12 to 24 patients per cycle, randomly assigned to three intervention groups.
Inclusion Criteria:
To participate in the study, patients must meet the following criteria:
Exclusion Criteria:
Exclusion criteria include:
Treatment-as-usual (TAU) delivered by psychiatrists and psychiatric nurses in HUS Psychiatry Outpatient Clinic for Psychosis. Participants who randomized to TAU -group, may receive medication for insomnia, but they will not received CBT-I. Treatment-as-usual is included in all intervention groups.
TAU and Internet-Based Cognitive Behavioral Therapy for Insomnia (iCBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I): There will be seven manualized sessions, conducted at intervals of either every one or two weeks. HUS iCBT-I, is based on the same theoretical model of insomnia as described in Morin 2003 and Edinger 2015- and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. iCBT-I consists of psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep. During the therapy, the therapist monitors progress at least once a week, sends messages to the participant, and answers any treatment-related questions. The aim of the feedback is to comment on exercises, clarify intervention and motivate the patient to persist the in carrying out the treatment and the requested behavioral changes.
Behavioral: iCBT-I
TAU and Cognitive Behavioral Group Therapy for Insomnia (GCBT-I): There will be six 90-minute manualized sessions, conducted at intervals of either one or two weeks. One booster session will be conducted one month after the treatment. Each group will have 4-8 people. The content of the CBT-I group is based on CBT for insomnia (as described above) and a previously published insomnia treatment manual for psychotic patients (Waters 2017).To ensuring the rights, safety and wellbeing of participants during the COVID-19 (Coronavirus) pandemic, we produce GCBT-I via internet.
Behavioral: GCBT-I
Internet-Based Cognitive Behavioral Therapy for Insomnia (ICBT-I) with the support of a therapist, delivered by mobile application (HUS iCBT-I)
Cognitive Behavioral Group Therapy for Insomnia (GCBT-I)
Change in Insomnia Severity Index score (ISI) (Morin 2011)
A 7-item questionnaire used to assess insomnia severity with a score ranging between 0 to 28. Each questionnaire item addresses an aspect about sleep that is rated by the respondent on a 5-point scale (i.e., 0=no problem to 4=very severe problem).
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Change in the health-related quality of life (HRQoL) instrument 15D score (Sintonen, 2001)
The 15D is a generic, comprehensive, 15-dimensional, standardized, self-administered measure of health-related quality of life (HRQoL) that can be used both as a profile and single index score measure. The maximum score is 1 (no problems on any dimension) and the minimum score is 0 (being dead).
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported subjective sleep quality collected through a digital smartphone app (AIDO Healthcare)
1-2 times a week by emoji scale 1-5
Time frame: baseline to week 36
Self-reported subjective fatigue collected through a digital smartphone app (AIDO Healthcare)
1-2 times a week by emoji scale 1-5
Time frame: baseline to week 36
Self-reported subjective mood collected through a digital smartphone app (AIDO Healthcare)
1-2 times a week by emoji scale 1-5
Time frame: baseline to week 36
Self-reported variables for sleep quantity and quality (adapted from Partinen 1996)
Questions about sleep quantity and quality
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for chronotype (Horne 1976)
Questions about chronotype (morningness-eveningness-)
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for dreaming and nightmares (adapted from Sandman 2015)
Questions about dreaming and nightmares
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for tiredness, fatigue, subjective memory, stress and recovery (Lundqvist 2016)
Questions about tiredness, fatigue, subjective memory, stress and recovery. Scale 1(very good) to 5(very poor).
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for functional ability (adapted from Tuomi 1998).
Questions about functional ability. Scale 0(very poor) to 10(very good).
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for symptoms of depression (Korenke 2001)
Questions about symptoms of depression. Scale 0(not at all) to 3 (Almost Always)
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for symptoms of psychosis (adapted from Haddoc 1999),
Questions about presence, severity, and characteristics of hallucinations, delusions, confused and disturbed thoughts and lack of insight and self-awareness.
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported variables for lifestyle
Questions about exercise, usage of caffeine, alcohol, nicotine.
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Subjective measures of Dysfunctional Beliefs and Attitudes about Sleep (DBAS-16) (Morin 2007)
DBAS-16 is a 16-item self reported questionnaire to measure people's beliefs and attitudes about their personal sleep situations. Items are ranked from 0, strongly disagree, to 10, strongly agree. Total score is mean of all questions, with a higher score representing more dysfunctional beliefs and attitude about sleep.
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Self-reported Feedback Questionnaire
Participants experiences from the intervention including habits of practice of the new skills, experience of the effect of the intervention on sleep, mood and lifestyle, alliance with the therapist, the positive and negative effects of the treatment are questioned after the treatment period.
Time frame: 12 weeks
Objective information on sleep from Actigraphy (ACG) data
The dataset from ACG includes Total Sleep Time (TST), Wake After Sleep Onset (WASO) Bed time, Get up time, Time in bed, Sleep efficiency (SE), Sleep Onset Latency (SOL), One minute immobility and Fragmentation index
Time frame: baseline (1 week) and week 12(1 week)
Objective information on circadian rhythms from Actigraphy (ACG) data
The dataset from ACG includes Cosine peak, Light/Dark ratio, Lowest 5 onset, Maximum 10 onset, RA, IV and IS
Time frame: baseline (1 week) and week 12(1 week)
Subjective sleep diary tracking
Each morning after waking participants completed the Sleep Diary during the ACG -monitoring period to provide a daily record of self-reported bedtime, get-up time, sleep duration, and daytime naps.
Time frame: baseline (1 week) and week 12(1 week)
Objective information on activity from EMFIT Sleep Tracker data (Emfit Ltd)
EMFIT device measures heart rate, breathing rate, movement activity every 4 seconds, sleep staging every 30 seconds, and heart rate variability every 3 minutes.
Time frame: baseline to week 13
Objective information on recovery of the autonomic nervous system from EMFIT Sleep Tracker data (Emfit Ltd)
EMFIT device measures heart rate, breathing rate, movement activity every 4 seconds, sleep staging every 30 seconds, and heart rate variability every 3 minutes.
Time frame: baseline to week 13
Cognitive performance is measure with the psychomotor vigilance test (PVT) (Basner 2011) via a web-based interface
PVT is a sustained-attention, reaction-timed task that measures the speed with which subjects respond to a visual stimulus
Time frame: baseline, 12, 24 and 36 weeks from the baseline
Plan to share: No — Upon completion of the clinical trial, data will be made available upon reasonable request and by the review of ethics Committee of the Hospital District of Helsinki and Uusimaa, Finland
Started Dec 2019 (actual). Primary completion is estimated for Sep 2024, 56 months after the start.
Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 56 months is above that.
Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sleep Initiation and Maintenance Disorders →
Helsinki University Central Hospital →